Imagia
Imagia is a Montréal-based AI healthcare company founded in 2014 that develops oncology-focused artificial intelligence solutions for pharmaceutical companies, medical device manufacturers, and clinical providers, with cumulative disclosed funding of approximately $37 million.
- Company typePrivate
- Founded2014
- HeadquartersMontréal, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Imagia does
Imagia is a Montréal-based AI healthcare company founded in 2014 that develops artificial intelligence solutions for pharmaceutical companies, medical device manufacturers, and clinical providers. The company's primary documented focus is oncology, specifically cancer care and oncology diagnostics and treatment. Imagia has pursued a vertical consolidation strategy, acquiring Cadens Medical Imaging in November 2017 to add AI medical imaging capabilities and Canexia Health in February 2022 to extend into clinical genomics and liquid biopsy oncology testing.
The company has cumulatively raised approximately $37 million across eight disclosed funding events between 2015 and December 2020, drawing capital from BDC Venture Capital, Real Ventures, Fidelity Canada, Amplitude Venture Capital, Desjardens-Innovatech, Emerillon Capital, Anges Québec, and Hacking Health Accelerator, plus a $3.00 million non-dilutive grant from the Government of Québec. Senior leadership comprises CEO Geralyn Ochab, CTO Florent Chandelier, CFO Anne-Marie Guertin, Chief Corporate Officer and co-founder Alexandre Le Bouthillier, and co-founder Nicolas Chapados, whose mandate covers AI scientific developments and strategic directions.
Imagia operates at a headcount of 11–50 employees and has not disclosed products, pricing, customer logos, distribution channels, or revenue figures in available sources. The company's primary domain (imagia.com) has expired and displays a Namecheap parking page as of the data collection date, a material operational signal that limits any conclusions about current commercial continuity.
Imagia firmographics
Firmographics- Name
- Imagia
- Legal name
- Imagia
- Website
- https://imagia.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Imagia is a Montréal-based AI healthcare company founded in 2014 that develops oncology-focused artificial intelligence solutions for pharmaceutical companies, medical device manufacturers, and clinical providers, with cumulative disclosed funding of approximately $37 million.
- Ownership category
- akta.pro rank
Imagia industry classification
Industry- Product category
- Healthcare AI Software
- NAICS
- Software Publishers (513210)
- SIC
- Services-Computer Integrated Systems Design (7373), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Imagia is headquartered
LocationHeadquarters
- HQ city
- Montréal
- HQ country
- Canada
- HQ region
- North America
Markets served
Imagia business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Imagia product offering
Product offeringCore offering
Imagia develops and sells AI-powered healthcare platforms focused on oncology and medical imaging. The company provides artificial intelligence solutions for clinical decision support, medical image analysis, and cancer genomics to pharmaceutical companies, medical device manufacturers, and clinical providers. Its offerings enable automated detection, classification, and treatment planning through proprietary deep learning and machine learning models.
Differentiator
Problem solved
Functional benefit
Products and services
- Imagia AI Healthcare Platform AI-powered healthcare platform for oncology that provides clinical decision support, medical imaging analysis, and cancer genomics capabilities for pharmaceutical companies, medical device manufacturers, and clinical providers.
- Cadens Medical Imaging Solutions Medical imaging AI solutions acquired through the Cadens Medical Imaging acquisition, providing AI-based analysis and interpretation capabilities for radiology and oncology imaging workflows.
- Canexia Health Cancer Genomics Cancer genomics and precision oncology solutions acquired through the Canexia Health acquisition, providing genomic testing and analysis capabilities to support precision cancer treatment and clinical decision making.
Companies that use Imagia
Customer profileSegments1 record
Ideal customer profiles3 records
Imagia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Imagia partnerships and signals
Strategic signalExpansion highlights3 records
Imagia competitors and assessment
Company assessmentDirect peers
- DeepHealth (RadNet): AI imaging subsidiary of RadNet commercializing clinical AI for radiology workflows. Comparable to Imagia's clinical provider AI imaging footprint and its Cadens Medical Imaging acquisition lineage.
- PathAI: AI-driven pathology platform with deep oncology focus, used by pharma and clinical providers. Directly comparable to Imagia as an AI healthcare partner operating in oncology diagnostics, with analogous multi-stakeholder (pharma + clinical) go-to-market.
- Arterys: Cloud-native AI platform for medical imaging analytics (cardiac, lung, oncology-adjacent). Compares to Imagia's medical imaging AI lineage through Cadens Medical Imaging, with similar SaMD-style positioning for clinical providers.
- Tempus Labs: AI-enabled precision medicine company combining clinical and molecular data for oncology. Like Imagia, it serves pharma, providers, and device partners with an integrated oncology AI stack spanning genomics and imaging-adjacent analytics.
- Qure.ai: AI medical imaging vendor with FDA-cleared and CE-marked radiology AI products used in clinical workflows. Comparable to Imagia's SaMD positioning in imaging AI for clinical providers.
- Lunit: AI medical imaging company with oncology modules (chest, breast, pathology). Directly comparable as a clinical AI imaging vendor serving providers and device partners, overlapping with Imagia's imaging and oncology footprint.
- Owkin: Federated learning and AI platform focused on oncology and clinical research with pharma and hospital partners. Directly comparable to Imagia's positioning as an AI healthcare partner for pharma and clinical providers in oncology.
- Volpara Health Technologies: AI-powered breast cancer imaging analytics sold to clinical providers and device partners. Comparable as an oncology-imaging AI vendor serving providers with a similar clinical-decision-support value proposition.
- ConcertAI: AI SaaS platform for oncology real-world evidence and clinical decision support. Comparable as an AI healthcare partner serving pharma and clinical providers in oncology with analytics and decision-support products.
- Zebra Medical Vision (Nanox): AI imaging analytics platform offering broad radiology AI to providers and embedded AI for imaging device OEMs. Comparable to Imagia's medical imaging AI capability and multi-stakeholder (provider + device) business model.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Imagia social profiles
Digital presenceImagia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Imagia leadership team
Management profileNumber of profiles
Profiles5 records
Imagia funding detail
Funding detailFunding overview
Funding rounds8 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Imagia M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Imagia
What does Imagia do?
Imagia develops and sells AI-powered healthcare platforms focused on oncology and medical imaging. The company provides artificial intelligence solutions for clinical decision support, medical image analysis, and cancer genomics to pharmaceutical companies, medical device manufacturers, and clinical providers. Its offerings enable automated detection, classification, and treatment planning through proprietary deep learning and machine learning models.
Is Imagia a public or private company?
Imagia is a private company. It is classified as venture growth investor backed and is currently operating.
When was Imagia founded?
Imagia was founded in 2014. It employs 11 to 50 people.
Where is Imagia based?
Imagia is headquartered in Montréal, Canada, in the North America region.
Who are Imagia's main competitors?
Direct peers on record are DeepHealth (RadNet), PathAI, Arterys, Tempus Labs, Qure.ai, Lunit, Owkin, Volpara Health Technologies, ConcertAI and Zebra Medical Vision (Nanox).
Does Imagia have an API?
No public API is recorded for Imagia.
What industry is Imagia in?
Imagia's product category is Healthcare AI Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 513210 and its SIC code is 7373.